SMO and Secretory Meningioma: Non-NF2 mutations, most frequently in TRAF7, KLF4, AKT1, SMO, PIK3CA, POLR2A, SMARCE1, SMARCB1, and PBRM1 define distinct genotype-phenotype subgroups with characteristic locations and histologies, such as the KLF4 + TRAF7 combination associated with secretory meningioma [6,21]. Chromosomal losses involving 1p, 6q, and 14q are strongly linked to higher WHO grades and recurrence risk [6].